China

AAV gene therapy
#AAV #Animal models #CANbridge Pharmaceuticals #Cell and gene therapy #China #Gene therapy #License agreement #Muscular dystrophy

Chinese biotech company consolidates gene therapy portfolio

CANbridge Pharmaceuticals has exercised its option to secure the exclusive global rights to develop, manufacture and commercialise a novel gene therapy to treat spinal muscular atrophy (SMA) from UMass Chan Medical School.  Animal data presented in 2022 showed that the gene therapy outperformed the benchmark therapy along… Read More

#News

Non-alcoholic fatty liver disease
#China #Clinical trials #Liver disease #Market reporting #Pharmaceuticals

China’s clinical trial activity in NAFLD increasing

China is expected to record the highest diagnosed prevalence of non-alcoholic fatty liver disease (NAFLD) in 2029, representing 44% of cases within the 16 major pharmaceutical markets (16MM).   As a result, the number of clinical trials conducted in the country for this indication is gradually increasing, driven mostly by international… Read More

#Business & Investment #News

#Biologics / Biotechnology #CAR-T #China #CRISPR #Drug discovery #Gene editing #Genetics / genomics #HIV #HPV #Oncology #Pharmacology #T cell activation #The Dose

The Dose: DDW’s drug discovery highlights

DDW highlights the most interesting global news and comments within the drug discovery and development sector this month.   Everyone enjoys a good news story and the drug discovery and development sector is no exception. Seeing tangible results of drug efficacy or therapeutics programmes can take years so it was heartening… Read More

#Exclusive Content